1. Home
  2. Topics
  3. The First Dosing of RQ-00000010 at Virginia Commonwealth University Initiated

Topics

The First Dosing of RQ-00000010 at Virginia Commonwealth University Initiated

 RaQualia Pharma Inc. (RaQualia) today announced that the first dosing of RQ-00000010 (RQ-10) to Parkinson’s disease (PD) patients at Virginia Commonwealth University Parkinson's and Movement Disorders Center (VCU).

 

This investigator-initiated trial (IIT) is a randomized, double-blinded, placebo-controlled study which will evaluate safety and tolerability, pharmacokinetics, and efficacy on gastrointestinal symptoms of RQ-10 in patients with PD.

 

There is a need for effective drug for the treatment of gastrointestinal symptoms such as gastroparesis and constipation in PD patients. Successfully completion of this study is expected to advance RQ-10 toward important therapy for the unmet medical need in PD patients.

 

In May 2014, RaQualia and VCU entered into a collaboration agreement to investigate RQ-10 for the treatment of the PD-associated gastrointestinal symptoms. In April 2016, VCU won a grant, US$868,000 in three years, for this IIT from the Michael J. Fox Foundation for Parkinson's Research.

 

 

[About RQ-10]

RQ-00000010 is a 5-HT4 receptor partial agonist with superior potency and selectivity compared to the existing medicines with the same mechanism of action. In non-clinical pharmacological studies, RQ-10 exhibited potent effects on GI motility enhancement. The FIH clinical trial of RQ-10 conducted in United Kingdom successfully demonstrated the activation of gastric emptying in healthy volunteer as well as safety and tolerability, and these results promoted us to enhance the clinical development of RQ-10 aggressively.

 

[About the Virginia Commonwealth University Parkinson's and Movement Disorders Center]

The Virginia Commonwealth University Parkinson's and Movement Disorders Center strives to be a premier model for improving the lives of individuals with movement disorders, their families and the community by its commitment to excellent in comprehensive, interdisciplinary clinical care, translational research and education and outreach.

For more information, visit: http://parkinsons.vcu.edu/.

 

####

Page Top

Corporate Information
CEO Message
Company Overview
Vision, Management Principle and Culture
Quality Policy
Corporate Governance
Business Model
Origins of Our Corporate Name and Logo
Access
Press Release
Research & Development
Collaboration
Partnering in Research
What are Research Tools?
Research Tool Licensing
Product Information
Anidulafungin
Ziprasidone
Dalbavancin
Potassium-Competitive Acid Blocker
5-HT4 Partial Agonist
5-HT2B Antagonist
Motilin Receptor Agonist
Licensing Status
Shareholder and Investor Information
Vision, Management Principle and Culture
Corporate Governance
Outline of Securities Matters
IR Library
IR Calendar
Disclaimer
IR Related News
Understanding RaQualia Pharma! RaQualia FAQ
RaQualia's History
What does RaQualia Pharma do?
How Does RaQualia Earn Revenues?
What About Dividends?
What are RaQualia's strengths?
What Does the Future Hold for RaQualia Pharma?
Contributions to Society
Corporate Contributions
Contributions to the Community
Press Release
Topics